GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Valuation Rank

PixarBio (PixarBio) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is PixarBio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PixarBio Valuation Rank Related Terms

Thank you for viewing the detailed overview of PixarBio's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio (PixarBio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Valuation Rank
Comparable Companies
VSAR ARCT ASX:ZLD TSXV:ATE ASX:ANR XPAR:OSE NTRP OSL:HBC XKRX:216400 LSE:HVO OSTO:ACTI BCLI LSE:SCLP ROCO:6580 ASX:BOT LSE:RLM NBY ASX:AHZ NAVB SPHS
Traded in Other Exchanges
N/A
Address
200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155
Website
https://www.pixarbio.com
PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.